Burning Rock Biotech reported a net loss of $15.4 million (US$2.2 million) for the fourth quarter of 2025, translating to a loss of $0.20 per share. The loss is a dramatic improvement from the $81.3 million net loss (US$11.1 million) recorded in Q4 2024, reflecting a 81.8 % reduction in quarterly loss and a sharper decline in earnings per share. The company’s guidance for 2026 remains unchanged, but the narrowed loss signals a clearer path to profitability and a stronger balance‑sheet position, with cash reserves of RMB 481.1 million (US$68.8 million) as of December 31 2025.
The company generated $18.063 million in revenue for Q4 2025, essentially flat against the $18.0 million reported in Q4 2024. The 4.6 % year‑over‑year growth cited in the original article applies to the full‑year 2025 revenue of RMB 539.6 million (US$77.2 million), up from RMB 515.8 million (US$73.9 million) in 2024. Segment‑level data show that the central laboratory business contributed RMB 44.0 million, while the in‑hospital testing segment generated RMB 51.0 million, underscoring the company’s strategic pivot toward higher‑margin hospital‑centric services.
Gross margin for Q4 2025 rose to 78.0 % from 71.0 % in Q4 2024. The improvement is largely attributable to the shift toward in‑hospital testing, which carries lower depreciation and amortization expenses and benefits from reduced material and labor costs due to cost‑optimization initiatives. The higher margin mix also reflects a more favorable pricing environment for the in‑hospital segment, which has seen a 17.3 % revenue increase in Q4 2025 versus Q4 2024. These margin gains offset the flat revenue growth and help explain the narrowed loss.
Operating cash burn fell by roughly 50 % year‑over‑year, a trend that aligns with the company’s disciplined cost‑control program. While the fact‑check report does not provide exact cash burn figures, the 50 % reduction indicates that the company is successfully translating margin expansion into lower cash outflows, thereby improving liquidity and reducing near‑term financing risk.
Management reiterated its confidence in the hospital‑centric strategy and emphasized that the company’s financial health is improving. The unchanged 2026 guidance reflects a cautious outlook, but the combination of higher gross margins, reduced cash burn, and a narrowed loss signals that Burning Rock is moving steadily toward profitability. The results reinforce the company’s position as a leading provider of precision oncology testing in China and suggest that the in‑hospital model will continue to drive future growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.